Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05415410 · ClinicalTrials.gov registry record · Phase 2
Proof-of-concept Trial of Apraglutide in Acute Graft Versus Host Disease (aGVHD)
A Phase 2 study, sponsored by VectivBio.
- Terminated
- Registry status
- Phase 2
- Development phase
- 31
- Enrollment target
NCT05415410: Clinical Trial Phase 2 study, sponsored by VectivBio.
NCT05415410 is a Phase 2 study that was terminated before completion, run by VectivBio. The registered enrollment target is 31 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (77% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05415410, a Phase 2 study, was terminated before completion, sponsored by VectivBio.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 31 participants
- Enrollment target
Study Summary
The aim of this trial is to assess safety and efficacy of apraglutide in subjects with steroid refractory gastrointestinal aGVHD.
Primary Outcome
AE=any untoward medical occurrence which does not necessarily have a causal relationship with study drug. Serious AE (SAE)=any AE that: results in death; is life-threatening; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect in a neonate/infant born to a mother or father exposed to study drug; is a clinically significant event in the Investigator's judgment. Treatment-em
Interventions
- DRUG Apraglutide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 31 participants |
| Start Date | 2022-05-25 |
| Est. Completion | 2024-12-17 |
| Phase | Phase 2 |
Why NCT05415410 stopped before completion
NCT05415410 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 31 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (77% lower).
The record links to 0 conditions, and to 1 intervention - of which Apraglutide is the first listed.
NCT05415410 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05415410 about?
NCT05415410 is a clinical study titled "Proof-of-concept Trial of Apraglutide in Acute Graft Versus Host Disease (aGVHD)". The aim of this trial is to assess safety and efficacy of apraglutide in subjects with steroid refractory gastrointestinal aGVHD.
What is the current status of trial NCT05415410?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 31 participants. The study started on 2022-05-25. Estimated completion is 2024-12-17.
What interventions are being tested in trial NCT05415410?
The interventions under investigation include: Apraglutide (DRUG).
Who is sponsoring clinical trial NCT05415410?
This trial is sponsored by VectivBio, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05415410's enrollment target sits among peer trials
31 1578th of 2000 higher than 419 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02932618 · 31 participants · Phase 3
A Study of Recombinant Von Willebrand Factor (rVWF) With or Without ADVATE in Children With Severe Von Willebrand Disease (VWD)
- NCT03482297 · 31 participants · Phase 1
Automated Abdominal Binder for Orthostatic Hypotension
- NCT04016389 · 31 participants · NA
FIGO 2018 Stage IB2 Cervical Cancer Treated With Neoadjuvant Chemotherapy Followed by Fertility Sparing Surgery
- NCT04211675 · 31 participants · Phase 1
NK Cells Infusions With Irinotecan, Temozolomide, and Dinutuximab
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI